Pfizer Acquires Metzera to Boost Obesity Pipeline

about 1 month ago

Tom Keen with Paul Sweeney and Bloomberg's John Tucker

"New York-based Pfizer. They're going to pay $4.9 billion for an obesity startup. The name of this company, Metzera. It is publicly traded. ... They're going to buy Metzera for $47.50 in cash. And then, to complicate things, they're going to have further payments of up to $22.50 per share if three specific and regulatory milestones are met. So it's a total potential value of this deal of $7.3 billion. And it represents a 43% premium. ... Pfizer's in the process of rebuilding in the aftermath of the pandemic."

Pfizer is executing a significant acquisition of Metzera, a publicly traded obesity startup, at a notable 43% premium. The deal includes an upfront cash payment and additional contingent payments based on regulatory milestones. This move is part of Pfizer's broader strategy to rebuild and diversify its pipeline post-pandemic, with the acquisition potentially enhancing its competitive position in the obesity treatment market, especially given the once-a-month dosing approach.

Related Stocks